PMID- 25535489
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141223
LR  - 20200930
IS  - 1710-1484 (Print)
IS  - 1710-1492 (Electronic)
IS  - 1710-1484 (Linking)
VI  - 11
IP  - 1
DP  - 2015
TI  - Initiation of immunoglobulin therapy by subcutaneous administration in 
      immunodeficiency patients naive to replacement therapy.
PG  - 63
LID - 10.1186/s13223-014-0063-8 [doi]
LID - 63
AB  - BACKGROUND: Patients with immunodeficiency diseases require lifelong treatment 
      with immunoglobulin (Ig), yet few studies have vetted dosing strategies and 
      effectiveness of Ig in older patient populations. Patients requiring subcutaneous 
      (SC) Ig (SCIG) typically start with intravenous dosing before transitioning to 
      SCIG weekly maintenance. In this retrospective review, we investigated an 
      alternate strategy with higher initial SC doses among an older patient population 
      with antibody deficiency syndromes. FINDINGS: Records of 13 patients (mean age, 
      70 years) with antibody deficiencies who were naive to treatment with Ig were 
      assessed. SCIG (Vivaglobin(R) [Immune Globulin Subcutaneous (Human), 16% Liquid] or 
      Hizentra(R) [Immune Globulin Subcutaneous (Human), 20% Liquid]) was given twice 
      weekly (100 mg/kg) for 2 weeks, followed by weekly (100 mg/kg) administration The 
      mean pretreatment IgG level was 460 mg/dL; at 1, 3, and 6 months after SCIG 
      initiation, mean IgG serum levels were 852, 907, and 943 mg/dL, respectively. 
      Maintenance doses were unchanged during 6 months of follow-up. All patients 
      remain on SCIG (median, 44 months). One patient developed sepsis/cholangitis 
      unrelated to treatment 3 months after starting SCIG; no other serious bacterial 
      infections were reported. CONCLUSIONS: Initiation of SCIG by doubling the 
      maintenance dose over 2 weeks may be a well-tolerated and effective option for 
      patients with antibody deficiencies requiring Ig replacement, especially among 
      older patients.
FAU - Koterba, Alan P
AU  - Koterba AP
AD  - Allergy Associates of the Palm Beaches, 840 US Highway 1, Suite 235, North Palm 
      Beach, FL 33408-3340 USA.
FAU - Stein, Mark R
AU  - Stein MR
AD  - Allergy Associates of the Palm Beaches, 840 US Highway 1, Suite 235, North Palm 
      Beach, FL 33408-3340 USA.
LA  - eng
PT  - Journal Article
DEP - 20141206
PL  - England
TA  - Allergy Asthma Clin Immunol
JT  - Allergy, asthma, and clinical immunology : official journal of the Canadian 
      Society of Allergy and Clinical Immunology
JID - 101244313
PMC - PMC4273447
OTO - NOTNLM
OT  - Globulins
OT  - Immune
OT  - Immunoglobulin therapy
OT  - Immunoglobulins
OT  - Immunological deficiency syndromes
OT  - Intravenous
OT  - Subcutaneous
EDAT- 2014/12/24 06:00
MHDA- 2014/12/24 06:01
PMCR- 2014/12/06
CRDT- 2014/12/24 06:00
PHST- 2014/06/03 00:00 [received]
PHST- 2014/11/21 00:00 [accepted]
PHST- 2014/12/24 06:00 [entrez]
PHST- 2014/12/24 06:00 [pubmed]
PHST- 2014/12/24 06:01 [medline]
PHST- 2014/12/06 00:00 [pmc-release]
AID - 63 [pii]
AID - 10.1186/s13223-014-0063-8 [doi]
PST - epublish
SO  - Allergy Asthma Clin Immunol. 2014 Dec 6;11(1):63. doi: 10.1186/s13223-014-0063-8. 
      eCollection 2015.